ROCK2 and chronic graft versus host disease: It has demonstrated efficacy in chronic graft-versus-host disease (cGVHD) [126,127], where selective ROCK2 inhibition attenuates fibrosis by regulating CTGF and modulates regulatory T-cell function through STAT3/STAT5 signaling pathways, resulting in a significant reduction of inflammation and tissue remodeling [15].